Shares of the pharmaceutical giant gained after a late-stage study showed its blockbuster drug Keytruda, combined with Kelun-Biotech's experimental therapy, improved outcomes for lung cancer patients.
Nebius Group stock gained after the company announced a new partnership model to expand its AI cloud platform globally, an asset-light strategy that relies on partners to fund and operate data centers.
Insiders at cybersecurity firm Netskope Inc. made significant share purchases, according to recent SEC filings, while executives at Broadcom, Arista Networks, and Lam Research sold substantial holdings.
Veradermics Inc. shares surged after the company announced positive Phase 2 clinical trial results for its oral drug candidate, VDPHL01, for treating female pattern hair loss.
KB Securities argues that a recent 30% drop in Samsung Electronics' stock is driven by 'overblown concerns,' stating that a historic chip shortage fueled by AI demand is expected by 2027.
The pharmaceutical company's stock gained after announcing successful outcomes in two late-stage studies for its cancer drug Keytruda, one in endometrial cancer and another in a difficult-to-treat lung cancer.
The optics and imaging systems provider announced a significant follow-on purchase order from a major technology customer, driving its stock up and highlighting a strategic shift to its proprietary materials.
Shares of Celcuity fell after the company secured its first FDA approval for a breast cancer treatment, as investor focus shifted to a delayed commercial launch and concerns over the drug's side effects.
Morgan Stanley reported one of its strongest quarters in history, with record revenue and a significant earnings beat, yet its shares declined as investors took profits amid already high expectations.
